Our Team
Scientific Team
Our multidisciplinary team is united by a shared goal: developing life-changing therapies for underserved patients.
After a first career path as physician-scientist in Infectious Diseases at La Pitié-Salpêtrière hospital (Paris), Ousmane Alfa Cissé has over 23 years of successful experience in pharmaceutical industry, in clinical-stage, mid-size to large companies at country and Global level. Prior to joining Nuvamid, he held various positions and Medical Affairs appointments as Country Medical Director for Sickle Cell Disease (SCD) at Pfizer and Global Blood Therapeutics, Global Medical Lead for rare blood disorders, and has led Immunology Franchise with LFB Biomédicaments, where he was responsible for the strategic coordination with LFB US affiliate and US joint venture (HEMA Biologics). Before, he was Senior Medical Advisor at Shire and Ipsen Pharma.
Dr Alfa Cissé holds a MD degree and is also graduated in Life and Health Sciences from Paris Universities. His main areas of expertise are highly specialized therapeutic areas in Rare Diseases, including rare/immune hematology diseases (SCD, hemophilia, von Willebrand disease, Primary Immune Thrombocythopenia, Essential Thrombocythemia). With a proven track record of rapidly increasing company footprint, he actively took part in the international launch of strategic products (US, EU, UK).
Pierre A. MORGON is CEO of MRGN Advisors, Chief Business Officer at Nuvamid, Co-Founder and interim CEO at Ibex Therapeutics, Co-Founder and Director at Anemos Therapeutics, Interim General Manager at Molsid and Regional Partner for Switzerland at Merieux Equity Partners.
He is Chairman of the Boards of Kupando, Limula and Health Technologies Holding, as well as Non-Executive Director to the Boards of Barinthus Bio, Univercells, Zambon Biotech, Lys Therapeutics, IABS (International Alliance for Biological Standardization) and GCRI (The Global Centre for Risk and Innovation).
Pierre has over 35 years of experience in the global life science industry, especially with specialty care, vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level in multinational corporations and as CEO of start-up companies.
He is a lecturer in several MBA programs and in life science conferences, and at the Mass Challenge incubator in Switzerland where he is a mentor for start-up life sciences companies.
He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA, and he is an alumnus of INSEAD and IMD.
Matthias Canault obtained a PhD in Nutrition in Aix-Marseille University (France) on inflammatory processes in the development of cardiovascular pathologies. He then spent 14 years working as a researcher in the field of thrombosis and hemostasis in France (Inserm, Marseille) and the United States (Harvard Medical School, Boston, MA) before joining the biotechnology sphere in 2018. He is deeply passionate about hematology and has dedicated part of his career to studying platelet function and signaling in rare platelet disorders (RASopahties and LAD type III). Highly passionate about science and new therapeutic challenges, Matthias Canault is currently working on the development of innovative molecular approaches to treat rare blood diseases using nucleotides involved in the synthesis of coenzymes central to cellular metabolism. Dr Matthias Canault manages Imalia’s development and innovation and provide scientific support for complex projects, from research to the clinic. Imalia’s Innovation and R&D department oversees collaborative programs as well as in-house R&D projects, ensuring that Imalia remains at the forefront of innovation and provide solutions to current and future therapeutic challenges in Rare Diseases.
Become Part of the Team
Are you passionate about transforming healthcare? We’re always looking for talented individuals to join our mission. Explore career opportunities and help us make a difference.